| Literature DB >> 32908536 |
Kezban Armagan Alpturker1, Ayse Beyhan Lale Cerrahoglu2, Ihsan Sebnem Orguc3.
Abstract
OBJECTIVE: Low-level laser therapy (LLLT) and extracorporeal shock wave therapy (ESWT) is applied in the conservative treatment of inflammatory plantar fasciitis, which is also a characteristic feature of spondyloarthritis (SpA) (Gill, 1997 and Roxas, 2005). We determined and compared the effectiveness of LLLT and ESWT using magnetic resonance imaging (MRI).Entities:
Year: 2020 PMID: 32908536 PMCID: PMC7474377 DOI: 10.1155/2020/4386361
Source DB: PubMed Journal: Int J Rheumatol ISSN: 1687-9260
Figure 1Flowchart of the study design. Abbreviations: ESWT: extracorporeal shock wave therapy; LLLT: low-level laser therapy.
Characteristics of the patients in the two study groups.
| LLLT group | ESWT group |
| All patients | ||
|---|---|---|---|---|---|
|
|
|
| |||
| Sex | Men | 10 (50%) | 10 (50%) | 1.00 | 20(50%) |
| Women | 10 (50%) | 10 (50%) | 20(50%) | ||
| Age | 37.00 ± 10.33 | 38.55 ± 9.57 | 0.620 | 37.78 ± 9.86 | |
| BMI (min–max) | 27.15 ± 4.99 (20.42-35.94) | 28.36 ± 5.17 (20.31-38.29) | 0.469 | 27.60 ± 5.05 (20.31-38.29) | |
| SpA period (year) (min–max) | 5.68 ± 5.11 (1.5-18) | 5.35 ± 4.87 (2-20) | 0.838 | 5.51 ± 4.93 (1.5-20) | |
| AS | 4 (20%) | 3 (15%) | 7 (17.5%) | ||
| PsA | 3 (15%) | 3 (15%) | 6 (15%) | ||
| EA | 0 | 2 (10%) |
| 2 (5%) | |
| ReA | 2 (10%) | 0 | 2 (5%) | ||
| uSpA | 11 (55%) | 12 (60%) | 23 (57.5%) | ||
| Heelpainduration | 18.75 ± 14.96 | 18.90 ± 16.68 | 0.976 | 18.83 ± 15.64 | |
| (month) | |||||
| (min–max) | (6-48) | (6- 60) | (6-60) | ||
Abbreviations: BMI: body mass index; AS: ankylosing spondylitis; PsA: psöriatic arthritis: EA: enteropathic arthritis; ReA: reactive arthritis; uSpA: undifferentiated spondyloarthritis.
Pre- and posttreatment AOFAS posterior foot score, RMS score, and VAS score first steps in the morning and VAS exercise results in the LLLT group (n: 20).
| Pretreatment | Posttreatment |
| |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| AOFAS posterior foot score | 64.30 ± 8.856 | 75.25 ± 2.447 | 0.001 |
| Roles-Maudley score | 2.95 ± 0.51 | 2.00 ± 0.56 | 0.001 |
| VAS score first steps in the morning | 69.75 ± 8.025 | 38.50 ± 12.042 | 0.001 |
| VAS exercise | 75.50 ± 9.720 | 48.50 ± 12.258 | 0.001 |
Pre- and posttreatment AOFAS posterior foot score, RMS score, and VAS score first steps in the morning and VAS exercise results in the ESWT group (n: 20).
| Pretreatment | Posttreatment |
| |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| AOFAS posterior foot score | 63.90 ± 11.59 | 75.80 ± 8.78 | 0.001 |
| Roles- Maudley score | 3.00 ± 0.64 | 1.85 ± 0.58 | 0.001 |
| VAS score first steps in the morning | 67.75 ± 8.95 | 34.50 ± 9.58 | 0.001 |
| VAS exercise | 78.00 ± 7.67 | 44.00 ± 13.43 | 0.001 |
Comparisons of the differences between posterior foot AOFAS before and after treatment, VAS score first steps in the morning and exercise, and Roles-Maudley score.
| LLLT group | ESWT group |
| |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| AOFAS difference | 10.65 ± 6.19 | 11.90 ± 6.83 | 0.548 |
| VAS exercise difference | 26.75 ± 7.65 | 34.00 ± 8.36 | 0.011 |
| VAS score first steps in the morning difference | 31.00 ± 7.71 | 33.25 ± 4.94 | 0.279 |
| Roles-Maudley score difference | 0.95 ± 0.60 | 1.15 ± 0.48 | 0.257 |
Results of clinical parameters evaluation in the LLLT group (n: 20).
| Pre-treatment | Posttreatment |
| |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| ASQoL | 12.00 ± 2.865 | 8.80 ± 2.375 | 0.001 |
| BASFI | 3.63 ± 0.75 | 3.05 ± 0.585 | 0.001 |
| BASDAI | 3.85 ± 0.480 | 3.57 ± 0.561 | 0.001 |
| MASES | 4.00 ± 1.55 | 3.20 ± 1.36 | 0.003 |
Results of clinical parameters evaluation in ESWT group (n: 20).
| Pretreatment | Posttreatment |
| |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| ASQoL | 11.45 ± 2.21 | 8.20 ± 2.66 | 0.001 |
| BASFI | 3.58 ± 0.850 | 2.94 ± 0.755 | 0.001 |
| BASDAI | 3.70 ± 0.512 | 3.31 ± 0.620 | 0.001 |
| MASES | 3.95 ± 1.14 | 3.55 ± 0.82 | 0.011 |
Comparison of differences between groups of pre- and posttreatment results of ASQoL, BASDAI, BASFI, and MASES.
| LLLT group | ESWT group |
| |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| ASQoL difference | 3.10 ± 1.61 | 3.25 ± 1.71 | 0.777 |
| BASDAI difference | 0.28 ± 0.23 | 0.38 ± 0.28 | 0.226 |
| BASFI difference | 0.57 ± 0.48 | 0.63 ± 0.37 | 0.663 |
| MASES difference | 0.80 ± 0.89 | 0.40 ± 0.59 | 0.104 |
Magnetic resonance imaging findings in the LLLT and ESWT groups.
| Before treatment | After treatment |
| |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| Plantar fascia thickness (mm) in the LLLT group | 4.43 ± 0.984 | 3.66 ± 0.613 | 0.001 |
| Plantar fascia thickness (mm) in the ESWT group | 4.50 ± 0.421 | 3.75 ± 0.423 | 0.001 |
| Plantar fascia difference in the treatment groups (mm) | 0.772 ± 0.549 | 0.750 ± 0.241 | 0.277 |
MASES and SpA disease duration correlation between plantar fascia thickness in MRI, ASQoL, BASFI, and BASDAI.
| Plantar fascia thickness in MRI (mm) | MASES before treatment | SpA disease duration | Plantar fasciitis duration | |
|---|---|---|---|---|
| ASQoL |
|
|
|
|
|
|
|
|
| |
| BASFI |
|
|
|
|
|
|
|
|
| |
| BASDAI |
|
|
|
|
|
|
|
|
|
r: correlation coefficient (0-0.25 = weak, 0.25-0.50 = medium, 0.50-0.75 = strong, and 0.75-1 = very strong).